Authors
Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, Andrea Ciarmiello, Ferdinando Squitieri, Vincenzo Silani
Publication date
2009/4/8
Journal
Neuropsychiatric Disease and Treatment
Pages
1-4
Publisher
Taylor & Francis
Description
Objectives
The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).
Methods and results
Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.
Conclusions
Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.
Total citations
201020112012201320142015201620172018201920202021202220232024417444565253635
Scholar articles
A Ciammola, J Sassone, C Colciago, NE Mencacci… - Neuropsychiatric Disease and Treatment, 2009